How are skeletal related events (SREs) prevented in patients with multiple myeloma (MM) receiving first-line therapy?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Bisphosphonates (eg, zoledronic acid, pamidronate) or denosumab for prevention of skeletal related events (SREs) should be considered for all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions. [47, 50]  See Guidelines/Management of Multiple Myeloma–related Bone Disease

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!